GlassScriptPhysician profile
Thomas William Hoang
NPI 1912090598
$7,776.61
in general payments reported to CMS, 2019-2025
28 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,180 · 2020: $1,019 · 2021: $1,202 · 2022: $352 · 2023: $1,599 · 2024: $2,300 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,679 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,678.67 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $345.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,529.02 | 2021-2025 | |
| Lundbeck LLC | $686.18 | 2020-2025 | Vyepti |
| Allergan, INC. | $685.93 | 2019-2020 | |
| Amgen INC. | $451.73 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $376.77 | 2019-2024 | Ajovy, Austedo Xr |
| Neurocrine Biosciences, INC. | $326.58 | 2019-2024 | Ingrezza |
| Pfizer INC. | $299.71 | 2023-2024 | |
| Lilly USA, LLC | $294.49 | 2019-2024 | Emgality |
| Biohaven Pharmaceuticals, INC. | $220.00 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $176.26 | 2019-2020 | |
| Argenx US, INC. | $117.81 | 2022 | |
| Eisai INC. | $78.96 | 2024 | |
| Bausch Health US, LLC | $57.80 | 2019 | |
| Currax Pharmaceuticals LLC | $52.10 | 2024 | Onzetra Xsail |
| Strongbridge US INC. | $45.69 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tonix Medicines, INC. | $41.32 | 2024 | Zembrace Symtouch |
| Genzyme Corporation | $41.10 | 2019 | |
| Sunovion Pharmaceuticals INC. | $39.83 | 2019 | |
| Ge Healthcare | $36.46 | 2019 | |
| Medtronic USA, INC. | $31.64 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.99 | 2022 | |
| Akcea Therapeutics, INC. | $28.78 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.93 | 2024 | Hyqvia |
| Otsuka America Pharmaceutical, INC. | $26.90 | 2023 | Rexulti |
| Genentech USA, INC. | $21.96 | 2024 | Ocrevus |
| Avanir Pharmaceuticals, INC. | $20.32 | 2019 | |
| Biogen, INC. | $15.69 | 2020 | |
| Acadia Pharmaceuticals INC | $15.66 | 2024 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hoang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.